Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Crucell « Terug naar discussie overzicht

DSM to offer human cell tech to Indian cos

17 Posts

Omlaag ↓

gogogoo 1 november 2007 22:01

DSM to offer human cell tech to Indian cos, plans tie-ups

29 Oct, 2007, 0053 hrs IST,Khomba Singh, TNN

NEW DELHI: Multi-billion-dollar pharma ingredient and chemicals major DSM is in talks with Indian biotech companies to outlicense its exclusive technology, which uses human cells to develop biotech drugs. The company is also looking for acquisitions and joint ventures with domestic drug manufacturers, in which it plans to have majority stake.

“Human cells provide twice the yield than animal cells. We have licensed this technology, which is used to develop biotech drugs from human cells to over 30 companies globally. We see no reason why Indian biotech and pharma companies should not use this technology. We are in talks with Indian biotech companies and pharma majors to outlicense this technology,” DSM chairman Feike Sijbesma told ET.

According to Mr Sijbesma, DSM is the only company in the world which has this technology. As Indian biotech and pharma majors increase their focus on the $65-billion biotech segment, the company is hopeful of a successful partnership with domestic players.

At present, the Dutch company revenues from India is around $200 million, which is less than one-fourth of the around $900 million it earns in China. DSM had started its operations in India and China at the same time, 20 years ago. However, the company is keen to expedite its growth in India and aims to triple its revenue from the country to $600 million by 2010.

Globally, the company has a turnover of e8 billion. DSM expects emerging markets such as India to play a key role in its future growth plans.

Mr Sijbesma said DSM is looking at expanding its operations in the country through both organic and inorganic route. He said: “We are looking at partnerships and JVs with Indian drug manufacturers. The company is in talks with some companies. In bigger companies, we would like to have 50% or more stake.”

However, he did not specify the profile of its target companies or the timeframe by when DSM expects to seal a deal. The company recently opened two units in Pune and Chandigarh.

economictimes.indiatimes.com/News/New...

Betreffende Sijbesma en PER.C6:

DSM-CEO: Chinese prijsconcurrentie blijvend lager
04 Oct 07, 15:04
HEERLEN (Dow Jones) - (Dow Jones) De prijsconcurrentie van Chinese concurrenten zal de komende jaren voor Koninklijke DSM nv blijvend lager zijn dan in het verleden, als gevolg van de beslissing van de Chinese overheid om een groot aantal voedingsbedrijven tijdelijk te sluiten om milieu- en gezondheidsredenen.
....knip....
Hoge verwachtingen heeft Sijbesma ten slotte ook van de 50/50 samenwerking met Crucell nv voor de menselijke cellijn PER.C6. Het product is al in licentie gegeven aan partijen als Merck en Pfizer. Mochten deze op basis van PER.C6 een nieuw medicijn op de markt gaan brengen, dan zullen ze naast allerlei mijlpaalbetalingen, 2% aan royalties betalen.

"Dat kan dus enorm oplopen bij een groot medicijn," zegt Sijbesma. "We krijgen nu nog kleine betalingen omdat de medicijnen nog in de vroege ontwikkelfase zijn. Als deze in fase drie komen, dan worden de mijlpaalbetalingen echter al zeer interessant. Ik hoop dat we daar in de komende tijd wat meer over kunnen zeggen, nu durf ik echter nog geen concrete voorspellingen te doen."

www.dft.nl/wirefeed/DJN/DJN_REAL/2250...

[verwijderd] 1 november 2007 22:36

Whooooopieeee, Gogogoo

Dit zijn leuke dingen voor de gewone mensehhh.

AB voor het vinden.

bilbo3 1 november 2007 23:28

Persoonlijk geloof ik niet in een overnamescenario, maar in bovenstaand artikel van DSM wordt Crucell niet eens genoemd, het lijkt wel of PerC6 van DSM is. Ze doen net alsof Crucell al is overgenomen, zeker ook gezien het feit dat de licentie van vandaag alleen door DSM wordt gemeld en niet door Crucell.

josti5 1 november 2007 23:54

quote:
bilbo3 schreef:
Persoonlijk geloof ik niet in een overnamescenario, maar in bovenstaand artikel van DSM wordt Crucell niet eens genoemd, het lijkt wel of PerC6 van DSM is. Ze doen net alsof Crucell al is overgenomen, zeker ook gezien het feit dat de licentie van vandaag alleen door DSM wordt gemeld en niet door Crucell.

Yep: opvallende, nieuwe ontwikkeling.

Mr Greenspan 2 november 2007 01:22

quote:
josti5 schreef:
[quote=bilbo3]
Persoonlijk geloof ik niet in een overnamescenario, maar in bovenstaand artikel van DSM wordt Crucell niet eens genoemd, het lijkt wel of PerC6 van DSM is. Ze doen net alsof Crucell al is overgenomen, zeker ook gezien het feit dat de licentie van vandaag alleen door DSM wordt gemeld en niet door Crucell.
[/quote]

Yep: opvallende, nieuwe ontwikkeling.

Zijn ze vergeten een persbericht uit te geven dat ze een overnamebod op Crucell hebben gedaan? ;-) nou ja dan morgen maar.

Mr Greenspan 2 november 2007 01:26

quote:
gogogoo schreef:
"Dat kan dus enorm oplopen bij een groot medicijn," zegt Sijbesma. "We krijgen nu nog kleine betalingen omdat de medicijnen nog in de vroege ontwikkelfase zijn. Als deze in fase drie komen, dan worden de mijlpaalbetalingen echter al zeer interessant. Ik hoop dat we daar in de komende tijd wat meer over kunnen zeggen, nu durf ik echter nog geen concrete voorspellingen te doen."

De eer om daar iets meer over te zeggen komt m.i. toe aan Crucell.

Zodra de eerste grote mijlpaal betaling (van de velen?) binnen is wordt de markt wellicht wakker.

Mr Greenspan 2 november 2007 01:30

quote:
Mr Greenspan schreef:
[quote=josti5]
[quote=bilbo3]
Persoonlijk geloof ik niet in een overnamescenario, maar in bovenstaand artikel van DSM wordt Crucell niet eens genoemd, het lijkt wel of PerC6 van DSM is. Ze doen net alsof Crucell al is overgenomen, zeker ook gezien het feit dat de licentie van vandaag alleen door DSM wordt gemeld en niet door Crucell.
[/quote]

Yep: opvallende, nieuwe ontwikkeling.
[/quote]

Zijn ze vergeten een persbericht uit te geven dat ze een overnamebod op Crucell hebben gedaan? ;-) nou ja dan morgen maar.

Ik bedoelde uiteraard op 'PerC6 van Crucell'.

[verwijderd] 2 november 2007 07:51

Ik blijf het raar vinden dat bij de aanzegging om het bedrijf te splitsen in Vaccines and Protiens, er niet een Technology/services-poot is gevormd.

Ben zeer benieuwd waar Kruimer straks alles gaat onderbrengen. Liever verbijzonderen. Dan wordt het ook makkelijker om de waarde ervan te bepalen!
Dan wordt ook duidelijk dat het aandeel nu spotgoedkoop is.

Brus: doe es wat!

[verwijderd] 2 november 2007 08:05

CRUCELL EN DSM SLUITEN OVEREENKOMST MET RECEPTA BIOPHARMA 08:02:36

[verwijderd] 2 november 2007 08:08

DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.

Sittard/Leiden, The Netherlands, November 2, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.

About PER.C6® Technology
Crucell's PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com

About DSM Biologics
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, The Netherlands, was established in 1986 and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. For more information, please visit www.dsmbiologics.com

About DSM
DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com.

Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release.
Crucell has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". Crucell prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

DSM Pharmaceutical Products
Karen King
President
DSM Biologics
Tel: +1-973-257-8427
Karen.King@dsm.com

DSM Biologics
Marcel Lubben
Vice President
Marketing, Sales & NBD
Tel: +31-(0)46-477 3343
marcel-m.lubben@dsm.com Crucell N.V. Media:
Barbara Mulder
Director Corporate Communications
Tel: +31-(0)71-519 7346
press@crucell.com

Investors/Analysts:
Oya Yavuz
Director Investor Relations
Tel: +31-(0)71-519 7064
ir@crucell.com

[verwijderd] 2 november 2007 08:08

Published: 08:00 02.11.2007 GMT+1 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.

Sittard/Leiden, The Netherlands, November 2, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.

gogogoo 2 november 2007 09:47

Heeft Crucell al een verkoopkanaal im India eigenlijk? Zo niet dan is dit natuurlijk een goedkope manier om deze markt te betreden. Laat DSM het werk daar maar doen, die lijken zich met een vette deelname ook te willen commiteren aan die regio.

aossa 2 november 2007 11:57

Re India:

Novartis wil er uit, DSM wil er in ...
Indiërs zijn sterk in generieken en mogelijk straks ook biosimilars !

Laat DSM derhalve maar zijn gang gaan aldaar wat betreft de proteïne-tak.
Mogelijk kan DSM-Crucell ook nog wat Rabies etc. antibodie_bulkmateriaal wegzetten aan plaatselijke vaccine producenten.
De behoefte is er vast hoog en het geld voor vaccinnatiecampagnes moet van de regering komen, bevoordeligen ook graag hun plaatselijke producenten !
Het sleutelwoord: 'co-makership' !

gogogoo 2 november 2007 12:08

quote:
aossa schreef:
Re India:

Novartis wil er uit, DSM wil er in ...
Indiërs zijn sterk in generieken en mogelijk straks ook biosimilars !

Laat DSM derhalve maar zijn gang gaan aldaar wat betreft de proteïne-tak.
Mogelijk kan DSM-Crucell ook nog wat Rabies etc. antibodie_bulkmateriaal wegzetten aan plaatselijke vaccine producenten.
De behoefte is er vast hoog en het geld voor vaccinnatiecampagnes moet van de regering komen, bevoordeligen ook graag hun plaatselijke producenten !
Het sleutelwoord: 'co-makership' !

Vandaar ook die opmerking over een 50%-stake.

[verwijderd] 2 november 2007 13:02

New Hepatitis A vaccine launched

Pune, August 6: For the first time in the country, a hepatitis A vaccine was launched in the city on Monday that uses a new generation virosome technology.
Dr Christian Herzog, director of medical services, Berna Biotech, Switzerland — the brain child behind the technology — told media persons that the virosome uses a biodegradable delivery system and is the most natural way of presenting antigens to the immune system of the body. They elicit high immune response keeping jaundice at bay and score well over conventional vaccines on pain parameters, he said. Currently, the vaccine is available in more than 40 countries.

Vaccination is at present the only method for protection against Hepatitis A, said Dr Pramod Jog, consultant paediatrician and President of Indian Academy of Paediatrics, Pune branch.
The Hepatitis A virus (HAV) is quite active during rainy seasons and spreads fast in comparison to other viruses. It spreads easily in areas where there are poor sanitary conditions or where personal hygiene is not observed. The transmission is generally through the gastrointestinal route. “The first step to prevent the disease is to vaccinate the child during the second year of age,” informs Dr Herzog.
According to United Nations Children’s Fund (UNICEF), vaccine preventable diseases (VPDs) cause an estimated 2 million deaths or more every year. Till about 15 years ago Hepatitis A was considered as the disease of the childhood as most get exposed to the infection after five years. However, in the last five years, prevalence of Hepatitis A is also being observed in older age group of people between 15-20 years, doctors point.
The new vaccine is being marketed in India by Chiron Panacea Vaccines, a joint venture of Novartis Vaccines (formerly Chiron) and Panacea Biotec.
cities.expressindia.com/fullstory.php...

Vaccine to fight Hepatitis-A soon

12 Aug 2007, 0134 hrs IST , TNN
HYDERABAD: Set to be launched within a week, HAVpur, a vaccine for Hepatitis-A, is part of an emerging trend known as New Generation (NG) vaccines.

Though a Hepatitis-A vaccine has already been available for the past nine years with four Indian companies producing it, HAVpur vaccine of the Swiss company Chiron Panacea is entering into the fray with a claim that their product, developed by celebrated vaccinologist Christian Herzog, offers the least reactogenecity, or post-vaccine reactions like inflammation, and fever.

However, when the minimum cost of Hepatitis A vaccine is Rs 800, the new vaccine will cost about Rs 1,000. "It will not be manufactured in India, but will be imported from Switzerland,” said the company’s representative at a workshop on Friday.

Unlike Hepatitis B, which is a virulent disease that devastates the liver, Hepatitis A causes jaundice just for a few days.
Even in Hyderabad, the infant mortality rate is over 50 per cent, claimed the office-bearers of the Indian Association of Paediatrics.

"It could be attributed to the lack of vaccination for several preventable diseases that cause pneumonia, a major infection,” said Medical Education Additional Director Dr M Indra Sekhar Rao.
timesofindia.indiatimes.com/Hyderabad...
crucell.yourbb.nl/viewtopic.php?t=52
www.iex.nl/forum/topic.asp?forum=228&...

Published: 08:00 04.04.2007 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial

Leiden, The Netherlands, April 4, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that the Rabies monoclonal antibody product it is developing has entered a Phase I clinical study in India, four months after launching a similar study in the US. Crucell has developed a human monoclonal antibody product for the post-exposure prophylaxis of rabies, using Crucell's MAbstract® and Crucell's PER.C6® technologies. This second Phase I study is closely linked to the initial Phase I study that is currently being performed in the US. Both studies are conducted under FDA authority, the Indian Phase I study gained approval upon review by the Drug Controller-General of India (DCGI).

The clinical trial will be a randomized, double-blind, placebo controlled study in 44 healthy volunteers that will test the antibody product alone in a dose escalation as well as in combination with rabies vaccine. The study, funded by Crucell, will be conducted through a clinical research organization in Mumbai, India. The main parameters under investigation will be safety, tolerability and (rabies virus) neutralizing activity.

"We are very pleased that would could initiate this second Phase I trial, as it follows favorable interim safety and tolerability data from the initial US study," said Jaap Goudsmit, Chief Scientific Officer at Crucell. "The clinical testing of the Rabies antibody cocktail in Asia is the next important step for the program, as the global burden of Rabies is mostly affecting this continent. In addition to clinical evaluation of the rabies mAb cocktail in India, we are currently exploring the conduct of clinical trials in other Asian countries, including China."

Dr. Deborah Briggs, Director of the Alliance for Rabies Control added: "There is a tremendous need for additional sources of rabies immune globulins (RIG) throughout the world, especially in Asia where less than 3 % of patients undergoing post-exposure prophylaxis actually receive passive immune products. Hopefully, new Mab products like this one will soon be available to help to solve the shortage problem and save human lives."

About Rabies
Rabies is a viral disease of mammals most often transmitted through the bite of a rabid animal. The virus infects the central nervous system, causing encephalitis (inflammation of the brain) and ultimately death if medical intervention is not sought promptly after exposure.

There is no proven treatment for rabies once symptoms of the disease have appeared. Lethal rabies is prevented by post-exposure prophylaxis (PEP) via the combined administration of a rabies vaccine and RIG following the bite of a rabid animal. Neither vaccine nor RIG are effective independently of one another. Current supply and quality of rabies vaccine is sufficient, but RIG is in short supply and carries certain safety risks.

Crucell has conceived an antibody product that is produced using its PER.C6® technology, which offers large-scale manufacturing capabilities and production under serum-free culture conditions. Crucell's rabies monoclonal antibody cocktail offers the potential for replacing the traditional serum-derived products that are currently still in use for the treatment of rabies.

Rabies is prevalent in all the continental regions of Europe, Asia, America and Africa. Globally, approximately 10 million people a year are vaccinated after exposure to rabies. Some 40,000 to 70,000 people are thought to die of the disease each year, mainly in Asia and Africa.

About MAbstract® technology
Crucell's proprietary MAbstract® technology can be used to discover drug targets, such as cancer markers or proteins from infectious agents including bacteria and viruses, and identify human antibodies against those drug

gogogoo 2 november 2007 13:05

quote:
yuzu atluap schreef:
The new vaccine is being marketed in India by Chiron Panacea Vaccines, a joint venture of Novartis Vaccines (formerly Chiron) and Panacea Biotec.

Daar hebben we weer 2 bekenden.
Panacea met een pentavalent vaccin voor kinderziekten en Chiron(Novartis) die samen met Crucell(Berna) Quinvaxem doet.

[verwijderd] 5 november 2007 09:58

DSM invests in US probiotics company

Heerlen,NL,05-Nov-2007 08:15 CET

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a financing round in Ganeden Biotech, Inc., a US probiotics company which markets dietary supplements focused on digestive health. Ganeden’s products are based on its unique position in a spore forming and lactic acid producing bacterium, Bacillus coagulans. This investment will contribute to DSM’s innovation ambitions in the Nutrition cluster, where the company holds leading positions in the markets for ingredients for human and animal nutrition and health and personal care. In this USD 12 million round DSM was joined by Capital Resource Partners, a Boston, Massachusetts-based private equity firm.

Ganeden’s proprietary Bacillus coagulans strains, particularly GanedenBC30™, distinguish themselves from other probiotics particularly with respect to longer shelf life, better gastric acid survivability and resistance against temperature and pressure during processing. Currently the company sells its digestive health products in over 40,000 stores all over the US. Ganeden also runs a licensing business to exploit the potential of its BC strains in other applications such as animal feed, functional foods, feminine hygiene products and environmental solutions.

Krijn Rietveld, Senior Vice President New Business Development at DSM Nutritional Products comments: ‘The area of probiotics is exciting and quickly developing with applications in both human and animal health and nutrition. We think that Ganeden Biotech’s BC30 strains have unique properties which could enable many new probiotic applications in both food and feed that we want to follow closely as an area of potential future business for DSM. Besides our venturing investment we are currently evaluating possible further partnering with Ganeden for the development of specific applications.’

www.dsm.com/en_US/html/media/press_re...

17 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	865,36	+0,01	+0,00%	18 apr
AMX	926,60	+7,92	+0,86%	18 apr
ASCX	1.189,83	-18,08	-1,50%	18 apr
BEL 20	3.826,58	+32,01	+0,84%	18 apr
Germany40^	17.751,90	-85,50	-0,48%	18 apr
US30^	38.013,46	0,00	0,00%	18 apr
US500^	5.049,25	0,00	0,00%	18 apr
Nasd100^	17.548,80	0,00	0,00%	18 apr
Japan225^	38.001,71	0,00	0,00%	18 apr
WTI	82,08	0,00	0,00%	18 apr
Brent	86,99	0,00	0,00%	18 apr
EUR/USD	1,0623	-0,0021	-0,20%	05:07
BTC/USD	61.333,83	-2.253,95	-3,54%	05:06
Gold spot	2.398,19	+18,82	+0,79%	05:07